Home Tags Seattle Genetics

Tag: Seattle Genetics

Seattle Genetics buys Bristol-Myers Squibb’s Pharmaceutical Manufacturing Facility in Bothell, Washington

Seattle Genetics has agreed to purchase Bristol-Myers Squibb's pharmaceutical manufacturing facility in the North Creek area of Bothell, WA, a short drive from Seattle....

Winding-Down of Research Operations but Astellas Retains Promising Antibody-Drug Conjugate R&D...

In a surprise move to most, but expected by industry insiders, Astellas Pharma, a Japan-based company focusing on the development of novel treatments in Urology,...

Brentuximab Vedotin Approved by Health Canada for Post-ASCT Consolidation Treatment of...

Health Canada, the federal department responsible for helping Canadians maintain and improve their health, has issued a non-conditional marketing authorization for use of brentuximab...

Antibody-drug Conjugates: Technologies and Global Markets

Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new.  Due to many technological advances, recognition of appropriate target antigens, success...

Positive Results from Phase III ECHELON-1 Trial Evaluating Brentuximab Vedotin in...

ECHELON-1, a randomized, multicenter, phase III clinical trial evaluating brentiximab vedotin (Adcetris®) as part of a combination chemotherapy regimen in 1,334 patients with advanced...

Seattle Genetics Submits Supplemental Biologics License Application Brentuximab Vedotin in Cutaneous...

Seattle Genetics has submitted a supplemental Biologics License Application or BLA to the U.S. Food and Drug Administration (FDA) for brentuximab vedotin (Adcetris®) for...

Phase III CASCADE Clinical Trial of Vadastuximab Talirine in Frontline Acute...

Earlier today, Seattle Genetics confirmed that it discontinued the phase III CASCADE clinical trial of vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia...

Seattle Genetics and Immunomedics Terminate License Agreement for Sacituzumab Govitecan

Seattle Genetics and Immunomedics today confirmed that they have terminated their Exclusive Global Licensing Agreement for sacituzumab govitecan (IMMU-132), Immunomedics breakthrough therapy candidate to...

AACR 2017: Highlighting Leadership and Innovation in the Development of Antibody-Drug...

During the upcoming 108th Annual Meeting of the American Association for Cancer Research (AACR) to be held April 1 to 5, 2017, in Washington,...

U.S. FDA Lifts Clinical Hold Phase I Trials of Vadastuximab Talirine

The U.S. Food and Drug Administration (FDA) confirmed today that it has lifted the clinical hold on phase 1 trials of vadastuximab talirine (SGN-CD33A;...